Life Science Partners
LSP closes LSP 7 at EUR 1bn
The GP says it is the largest life sciences venture capital fund ever raised in Europe
EQT acquires LSP, forming EQT Life Sciences
Announcement follows Life Sciences Partners' seven-month, EUR 850m fundraise for LSP VII
Forbion et al. in $196m round for NewAmsterdam Pharma
Company intends to use the fresh capital to finance the full phase-III development of its obicetrapib drug
Life Science Partners et. al in series-A round for Vico Therapeutics
Biotech startup will use the proceeds to further advance its therapy
LSP invests €5m in Kiadis Pharma
Company is listed on the regulated market of Euronext Amsterdam and Euronext Brussels
LSP closes sixth fund on $600m
Fund invests in European companies developing new medications and medical technologies
LSP leads €10.5m series-D for Xeltis
Life Sciences Partners first invested in the medical devices company in 2014
LSP, Andera et al. invest €116m in AM-Pharma
Forbion, Ysios Capital and Idinvest also back the financing for the biopharmaceutical company
HTGF-backed Immunic lists on Nasdaq
Consortium including LSP, Bayern Kapital, HTGF and IBG reinvested €26.7m in Immunic
LSP in $50m series-A for Snipr Biome
Lundbeckfonden Emerge invested an undisclosed sum in an exploratory investment in 2017
Benelux venture fundraising outpaces buyout counterpart
Last year’s €887m committed to venture funds is the second highest ever seen in the region, after 2016’s record of €1.03bn
LSP leads €28m series-B for Atlantic Therapeutics
Andera Partners, Atlantic Bridge, Seroba and Earlybird also take part in the round
LSP leads $28m round for Lumeon
Healthcare software company will expand its US operations and invest in marketing
LSP raises €410m for sixth flagship fund
Netherlands-based life sciences specialist has raised €750m across three funds in 10 months
Andera and LSP lead $84m series-B for Artios
Biotech firm will undertake clinical proof-of-concept trials for its DNA polymerase theta programme
LSP closes €280m healthcare fund
Fund is the largest in Europe dedicated purely to medical technology investments
VC firms in $59.6m series-C for Hookipa
New investors include HB Partners, Hillhouse Capital, Sirona Capital and Gilead Sciences
Ysios Capital backs €45m series-C for Xeltis
Life Sciences Partners, Kurma Partners and VI Partners also took part in the round
LSP in €42m series-B for Nouscom
Abingworth leads the round with participation from 5am Ventures and Versant Ventures
Life Sciences Partners leads €31.7m series-A for Immunic
LSP led the round, which initially closed on €17.5m in 2016, with Omega and Fund+ joining
LSP leads €15m series-A for Cardior Pharmaceuticals
New funding will allow the company to develop its lead compound, which targets RNAs linked to heart failure
EMBL and Life Sciences Partners sell Luxendo to Bruker
Bruker will expand its portfolio with the addition of Luxendo's microscopes and intellectual property
BIVF at al. lead €20m series-A for ImCheck Therapeutics
Backers include Kurma Partners, Idinvest, Gimv and Life Sciences Partners
EMBL, Life Sciences Partners lead €8m series-A for Luxendo
GPs completed the funding round launched in 2015 with an additional €2m injection